A phase II single‐arm clinical study investigating the combined use of pembrolizumab with VEGFR inhibitor cabozantinib in 36 patients with R/M‐HNSCC demonstrated a median PFS of 14.6 months and median OS of 22.3 months [86]. The gene discussed is KDR; the disease is head and neck squamous cell carcinoma.